We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

19 hedge funds and large institutions have $2.43M invested in Cellectar Biosciences in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.09% less ownership

Funds ownership: 0.67% → 0.59% (-0.09%)

21% less funds holding

Funds holding: 24 → 19 (-5)

24% less capital invested

Capital invested by funds: $3.22M → $2.43M (-$785K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
19
Holders Change
-5
Holders Change %
-20.83%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$17.3K
2
UBS Group
UBS Group
Switzerland
+$731

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$284K
2
Citadel Advisors
Citadel Advisors
Florida
-$31.9K
3
Franklin Resources
Franklin Resources
California
-$17.7K
4
TRCT
Tower Research Capital (TRC)
New York
-$5.26K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.27K

CLRB Hedge Fund Activity: Q1 2023 in Review

19 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2023, worth a combined $2.43M — down 24% from $3.22M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CLRB and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $17.3K. The largest seller was CVI Holdings, exiting entirely with an estimated $284K sold.

  • 19 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2023, down from 24 in Q4 2022.
  • Funds reported $2.43M of Cellectar Biosciences stock for Q1 2023, down 24% quarter-over-quarter.
  • 0 funds opened new Cellectar Biosciences positions in Q1 2023 and 5 closed out, a net change of -5 holders.
  • The largest Cellectar Biosciences buyer in Q1 2023 was Renaissance Technologies, an estimated $17.3K added.
  • The largest Cellectar Biosciences seller in Q1 2023 was CVI Holdings, an estimated $284K sold.

Based on aggregated 13F filings for Q1 2023.